Display options
Share it on

Cancer Immunol Immunother. 1985;19(2):136-41. doi: 10.1007/BF00199722.

Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease in clinical remission.

Cancer immunology, immunotherapy : CII

A M Liberati, M Brugia, B S Edwards, P Bertoni, E Ballatori, A Puxeddu, F Grignani

PMID: 3872709 DOI: 10.1007/BF00199722

Abstract

Fifteen Hodgkin's disease patients (8 male, 7 female) aged 19-72 years, who had been in complete unmaintained remission for 1 year or more when the study was initiated, were given 50 mg thymostimulin (TS) IM daily for 60 consecutive days. When compared with 26-30 age- and sex-matched controls, as a group the patients' circulating ENR+, OKT+3, and OKT+4 cells were depressed (0.001 less than or equal to P less than or equal to 0.06), whereas their OKT+8 cell population was not. Low (greater than 1 SD or greater than 2 SD below mean in controls) or borderline (mean value of two subsequent tests greater than 1 SD below mean in controls) values of ENR+, OKT+3, and OKT+4 cells were seen in nine (group I) of the 15 patients tested, while the remaining six patients (group II) had normal T-cell proportions. Following TS treatment, the proportions of ENR+, OKT+3, and OKT+4 cells increased to normal in all group I patients. The T-cell levels, however, decreased to pretreatment values 60-70 days after completion of TS therapy. TS had no effect on the group II patients whose T-cell percentages had initially been normal. Spontaneous cell-mediated cytotoxicity (SCMC) was assessed in 11 patients, and irrespective of the baseline values, there was a significant enhancement (P less than 0.005) by day 15 of TS administration, which was maintained during treatment. SCMC, however, returned to pretreatment levels 60-70 days after TS was discontinued. The delayed skin test reactivity to DNCB was significantly depressed in all cases. Although TS restored the T-cell proportions, it failed to reverse DNCB reactivity from negative to positive in any of the patients tested. TS can thus restore defective T-cell frequencies and can enhance cytolytic functions that are potentially important in host immunosurveillance, but it apparently failed to improve the skin reactivity to neoantigen.

References

  1. J Immunol. 1976 Oct;117(4):1331-5 - PubMed
  2. Pediatr Res. 1979 Jul;13(7):797-802 - PubMed
  3. J Clin Invest. 1973 Aug;52(8):1908-17 - PubMed
  4. Cancer. 1982 Aug 1;50(3):490-7 - PubMed
  5. N Engl J Med. 1976 Dec 2;295(23):1314-5 - PubMed
  6. Scand J Immunol. 1978;7(6):511-4 - PubMed
  7. Cancer. 1979 Jul;44(1):106-11 - PubMed
  8. Cancer. 1976 Jan;37(1):98-103 - PubMed
  9. Clin Exp Immunol. 1980 Mar;39(3):551-61 - PubMed
  10. N Engl J Med. 1977 Nov 3;297(18):963-8 - PubMed
  11. N Engl J Med. 1974 Jan 24;290(4):181-6 - PubMed
  12. Clin Immunol Immunopathol. 1980 Feb;15(2):133-43 - PubMed
  13. Blood. 1981 Mar;57(3):607-13 - PubMed
  14. J Clin Invest. 1978 Jun;61(6):1620-7 - PubMed
  15. Cancer. 1981 Aug 15;48(4):964-73 - PubMed
  16. Blood. 1977 May;49(5):771-8 - PubMed
  17. Cancer. 1975 Sep;36(3):974-6 - PubMed
  18. Blood. 1978 Aug;52(2):261-71 - PubMed
  19. Blood. 1978 Mar;51(3):439-43 - PubMed
  20. Cancer. 1980 Apr 15;45(8):2102-8 - PubMed
  21. Cancer. 1977 Jul;40(1):14-9 - PubMed
  22. Cancer. 1978 Jul;42(1):133-9 - PubMed
  23. Cancer. 1980 Mar 1;45(5):899-905 - PubMed
  24. Semin Oncol. 1980 Jun;7(2):114-25 - PubMed
  25. Immunol Rev. 1979;45:163-93 - PubMed
  26. J Clin Invest. 1978 Jan;61(1):55-63 - PubMed
  27. Immunol Rev. 1981;56:89-114 - PubMed
  28. Ann Intern Med. 1979 Jun;90(6):892-5 - PubMed
  29. Cancer. 1981 Nov 1;48(9):2010-5 - PubMed
  30. Ann Intern Med. 1980 May;92(5):595-9 - PubMed
  31. Immunopharmacology. 1982 Oct;5(1):11-8 - PubMed
  32. Clin Exp Immunol. 1977 Jul;29(1):30-5 - PubMed
  33. Cancer. 1982 Jan 15;49(2):245-50 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources